A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer With Neuroendocrine Differentiation.
In: Hepatitis Weekly, 2023-02-06, S. 93-93
serialPeriodical
Zugriff:
EXPLORATORY OBJECTIVES: I. Evaluate the potential to perform patient-specific dosimetry of lutetium Lu 177 dotatate using gamma imaging to predict treatment response and renal toxicity. Patients with a pure neuroendocrine carcinoma histology do not need to be undergoing LHRH agonist/antagonist therapy No concurrent use of other anti-cancer therapies Pregnancy Precaution: The effects of lutetium lu 177 dotatate on the developing human fetus are unknown. [Extracted from the article]
Copyright of Hepatitis Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer With Neuroendocrine Differentiation.
|
---|---|
Zeitschrift: | Hepatitis Weekly, 2023-02-06, S. 93-93 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1086-0223 (print) |
Sonstiges: |
|